➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Dow
Baxter
Harvard Business School
AstraZeneca

Last Updated: March 6, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BIOTHRAX

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for BIOTHRAX

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01263691 Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults Completed Department of Health and Human Services Phase 1 2010-12-01 The purpose of this Phase 1 clinical trial is to evaluate the safety, tolerability, and immunogenicity of AV7909 anthrax vaccine in healthy adults. In this study, healthy male and female subjects between 18 and 50 years of age will receive vaccinations via the intramuscular (IM) route at Days 0 and 14. Safety and tolerability will be evaluated via laboratory tests, physical examinations, vital signs, adverse events (AEs), concomitant medications, and local and systemic signs and symptoms of reactogenicity.
NCT01263691 Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 2010-12-01 The purpose of this Phase 1 clinical trial is to evaluate the safety, tolerability, and immunogenicity of AV7909 anthrax vaccine in healthy adults. In this study, healthy male and female subjects between 18 and 50 years of age will receive vaccinations via the intramuscular (IM) route at Days 0 and 14. Safety and tolerability will be evaluated via laboratory tests, physical examinations, vital signs, adverse events (AEs), concomitant medications, and local and systemic signs and symptoms of reactogenicity.
NCT01263691 Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults Completed Emergent BioSolutions Phase 1 2010-12-01 The purpose of this Phase 1 clinical trial is to evaluate the safety, tolerability, and immunogenicity of AV7909 anthrax vaccine in healthy adults. In this study, healthy male and female subjects between 18 and 50 years of age will receive vaccinations via the intramuscular (IM) route at Days 0 and 14. Safety and tolerability will be evaluated via laboratory tests, physical examinations, vital signs, adverse events (AEs), concomitant medications, and local and systemic signs and symptoms of reactogenicity.
NCT01753115 Ciprofloxacin BioThrax Co-Administration Study Completed Department of Health and Human Services Phase 2 2012-12-01 The purpose of this clinical trial is to determine whether there is any effect on the antibiotic, ciprofloxacin when taken before and after administration of a 3-dose series of BioThrax® (Anthrax Vaccine Adsorbed or AVA). This study will be conducted in the United States (US) in 154 healthy male and female volunteer subjects ages 18 to 45. The duration of study participation for each subject will be approximately 76 days (approximately 2.5 months)
NCT01753115 Ciprofloxacin BioThrax Co-Administration Study Completed Emergent BioSolutions Phase 2 2012-12-01 The purpose of this clinical trial is to determine whether there is any effect on the antibiotic, ciprofloxacin when taken before and after administration of a 3-dose series of BioThrax® (Anthrax Vaccine Adsorbed or AVA). This study will be conducted in the United States (US) in 154 healthy male and female volunteer subjects ages 18 to 45. The duration of study participation for each subject will be approximately 76 days (approximately 2.5 months)
NCT03518125 BARDA Securing Anthrax Immunity For the Elderly Recruiting Rho, Inc. Phase 2 2018-05-09 This study is designed to assess the safety and ability of BioThrax and AV7909 anthrax vaccines to generate an immune response in adults ≥ 66 years of age in stable health in comparison to adults 18-50 years of age in stable health.
NCT03518125 BARDA Securing Anthrax Immunity For the Elderly Recruiting Biomedical Advanced Research and Development Authority Phase 2 2018-05-09 This study is designed to assess the safety and ability of BioThrax and AV7909 anthrax vaccines to generate an immune response in adults ≥ 66 years of age in stable health in comparison to adults 18-50 years of age in stable health.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for BIOTHRAX

Condition Name

Condition Name for BIOTHRAX
Intervention Trials
Anthrax 2
Bacillus Anthracis (Anthrax) Infection 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for BIOTHRAX
Intervention Trials
Anthrax 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for BIOTHRAX

Trials by Country

Trials by Country for BIOTHRAX
Location Trials
United States 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for BIOTHRAX
Location Trials
Utah 2
Texas 1
Nebraska 1
Missouri 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for BIOTHRAX

Clinical Trial Phase

Clinical Trial Phase for BIOTHRAX
Clinical Trial Phase Trials
Phase 2 2
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for BIOTHRAX
Clinical Trial Phase Trials
Completed 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for BIOTHRAX

Sponsor Name

Sponsor Name for BIOTHRAX
Sponsor Trials
Department of Health and Human Services 2
Emergent BioSolutions 2
National Institute of Allergy and Infectious Diseases (NIAID) 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for BIOTHRAX
Sponsor Trials
U.S. Fed 3
Industry 3
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Merck
Mallinckrodt
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.